Alkermes plc
IEFinancials
Valuation Metrics
Alkermes plc's Market Cap is $8.26B. At end of 2025 it was $4.61B. Ranked #1058 of 3,112 in US market (top 34%), #345 of 1,445 on NASDAQ (top 24%), #54 of 269 in Pharmaceuticals, Biotechnology & Life Sciences (top 20%) by Market Cap.
Investment Metrics(as of 2026-08-03)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $8.26B | US#1,058/3,112 Sec#54/269 |
| Revenue | $1.67B | US#1,595/3,112 Sec#43/269 |
| Net Income | $66M | US#1,759/3,112 Sec#62/269 |
| Total Assets | $4.39B | US#1,517/3,112 Sec#38/269 |
| Net Assets | $1.81B | US#1,326/3,112 Sec#42/269 |
| Employees | 2,050 | US#1,111/3,112 Sec#27/269 |
| Value | ||
| P/E | 124.85x | US#2,093/3,112 Sec#69/269 |
| P/B | 4.56x | US#2,094/3,112 Sec#132/269 |
| P/S | 4.95x | US#2,260/3,112 Sec#78/269 |
| EV/EBITDA | 42.73x | US#2,312/3,112 Sec#73/269 |
| FCF Yield | 2.68% | US#1,816/3,112 Sec#62/269 |
| Profitability | ||
| ROE | 3.66% | US#1,933/3,112 Sec#69/269 |
| ROA | 1.51% | US#1,745/3,112 Sec#70/269 |
| Op. Margin | 7.03% | US#1,886/3,112 Sec#72/269 |
| Revenue Growth | 26.97% | US#543/3,112 Sec#72/269 |
| Earnings Growth | -99.42% | US#2,063/3,112 Sec#65/269 |
| Financial Health | ||
| Debt Ratio | 142.91% | US#1,442/3,112 Sec#184/269 |
| Total Debt | $1.57B | US#1,264/3,112 Sec#32/269 |
| FCF | $222M | US#1,298/3,112 Sec#43/269 |
| Cash | $512M | US#1,055/3,112 Sec#54/269 |
| Current Ratio | 2.30x | US#1,088/3,112 Sec#216/269 |
| Net Debt/EBITDA | 4.87x | US#2,031/3,112 Sec#82/269 |
| Performance | ||
| 1Y Return | 86.55% | US#381/3,112 Sec#88/269 |
| 1M Return | -9.25% | US#2,552/3,112 Sec#159/269 |
| From 52W High | -11.03% | US#1,122/3,112 Sec#61/269 |
| 1Y MDD | -22.20% | US#846/3,112 Sec#42/269 |
| Trading | ||
| Volume | 1,798,061 shares | US#976/3,112 Sec#90/269 |
| Trading Value | $89M | US#992/3,112 Sec#59/269 |
| Per Share | ||
| EPS | $1.47 | US#1,448/3,112 Sec#49/269 |
| BPS | $11.05 | US#1,715/3,112 Sec#57/269 |
Company Info
Alkermes plc, a biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. The company has a portfolio of proprietary commercial products for the treatment of opioid dependence, alcohol dependence, schizophrenia, bipolar I, and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder; and LUMRYZ, an extended-release oral suspension product for the treatment of cataplexy or EDS in pediatric patients. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.